Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of bis(polysubstituted hexanoic acid) bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl) diphosphate and bis(polysubstituted hexanoic acid) 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl phosphate and polysubstituted hexanoic acid bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl) hydrogen diphosphate and polysubstituted hexanoic acid bis(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl) phosphate and polysubstituted hexanoic acid 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl hydrogen phosphate
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP screening study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- Male and female rats were administered the test substance once to generate preliminary pharmacokinetic data. Fat and liver were analysed for parent compound to provide an estimate of the tissue:plasma ratio.
- GLP compliance:
- no
Test material
- Reference substance name:
- TLF-11073
- IUPAC Name:
- TLF-11073
- Details on test material:
- - Purity: 19.7% solids in water
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 11 weeks
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: deionised water
- Duration and frequency of treatment / exposure:
- single dose
Doses / concentrationsopen allclose all
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Remarks:
- formulation adjusted for purity (19.7%)
- Dose / conc.:
- 30 mg/kg bw/day (nominal)
- Remarks:
- formulation adjusted for purity (19.7%)
- No. of animals per sex per dose / concentration:
- 3/sex/dose
- Control animals:
- no
- Positive control reference chemical:
- no
- Statistics:
- Two plasma analytes had sufficient data >LOQ to permit non-compartmental pharmacokinetic analysis: bis (1-octanol, 3,3,4,4,5,5,6,6,7,7, 8,8,8,-tridecafluoro) phosphate, lysine salt [abbreviated as P1OH2] and 6:2 FTCA (C6F13CH2COOH) which is a transient metabolite. Kinetic calculations were performed using WinNonlin® (Pharsight Corporation, Mountain View, CA, USA).
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Plasma concentrations of the mono, bis and pyro constituents (P1OH1, P1OH2 and P2OH2) were observed in both sexes at various time points after dosing indicating absorption.
- Details on distribution in tissues:
- After dosing, the parent fluorophosphate constituents were absorbed and distributed in plasma, fat and liver tissues of both male and female rats. In all tissues, the highest concentrations of the parent fluorophosphate was for the P1OH2 constituent. In vivo metabolism of the parent constituents occurred as evidenced by the appearance of a series of transient intermediate metabolites (6:2 FTCA and 6:2 FTUA) and perfluorocarboxylic acids (PFBA, PFHxA, PFHpA, 5:3 Acid).
There was no significant sex difference in the pharmacokinetic parameters for one of the major components, P1OH2. There was a slightly less than dose proportional increase in AUC for both male and female rats. As the dose was increased 3-fold from 10 to 30 mg/kg, AUC increased 2.0 and 2.4-fold for male and female rats, respectively. There was an apparent sex difference in the plasma pharmacokinetics of the metabolite, 6:2 FTCA at the 30 mg/kg dose level with females having an approximately 2.9 and 2.1 times greater Cmax and AUC, respectively, than males. Only component P1OH2 and the metabolite, 5:3 acid had tissue concentrations above the LOQ at sacrifice. Bis (P1OH2) was the only parent constituent consistently detected in both fat and liver tissue.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Concentrations of the following metabolites were quantified in the plasma of both sexes: 6:2 FTCA, 6:2 FTUCA, PFBA, PFHxA, PFHpA and 5:3 Acid. Plasma concentrations of 6:2 FTOH were not quantified (
Applicant's summary and conclusion
- Conclusions:
- The fluorophosphate constituents of the test substance were absorbed, distributed, metabolized and eliminated in vivo in rats.
- Executive summary:
The test substance was administered by oral gavage to male and female rats in a single dose of either 10 mg/kg or 30 mg/kg. Concentrations of the major fluorophosphate test substance constituents were analysed together with transient metabolic intermediates and terminal metabolism products at multiple time points for 168 hours after dosing. After animal sacrifice at 168 hours, tissue samples of fat and liver were analysed for the same suite of analytes and tissue/plasma concentration ratios were calculated. Non-compartmental pharmacokinetic analysis was performed on individual animal plasma concentration data.
The fluorophosphate constituents of the test substance were absorbed, distributed, metabolized and eliminated in vivo in rats. Metabolism was demonstrated by the formation and subsequent decline of a series of metabolic products including 6:2 FTCA, 6:2 FTUCA, PFBA, PFHxA, PFHpA and 5:3 Acid. The terminal elimination half-life of the parent bis constituent (P1OH2) ranged between 37 and 53 hours.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)